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Highlights 
 We validated statistical distance-aging associations in multiple human populations 
 In all populations, statistical distance increases with age and predicts mortality 
 This finding is not very sensitive to which biomarkers are used 
 Individual biomarkers alone behave differently across populations 
 These findings confirm that statistical distance measures physiological dysregulation 
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Abstract 18 
Measuring physiological dysregulation during aging could be a key tool both to understand underlying 19 
aging mechanisms and to predict clinical outcomes in patients. However, most existing indices are either 20 
circular or hard to interpret biologically. Recently, we showed that statistical distance of 14 common 21 
blood biomarkers (a measure of how strange an individual’s biomarker profile is) was associated with 22 
age and mortality in the WHAS II data set, validating its use as a measure of physiological dysregulation. 23 
Here, we extend the analyses to other data sets (WHAS I and InCHIANTI) to assess the stability of the 24 
measure across populations. We found that the statistical criteria used to determine the original 14 25 
biomarkers produced diverging results across populations; in other words, had we started with a 26 
different data set, we would have chosen a different set of markers. Nonetheless, the same 14 markers 27 
(or the subset of 12 available for InCHIANTI) produced highly similar predictions of age and mortality. 28 
We include analyses of all combinatorial subsets of the markers and show that results do not depend 29 
much on biomarker choice or data set, but that more markers produces a stronger signal. We conclude 30 
that statistical distance as a measure of physiological dysregulation is stable across populations in 31 
Europe and North America. 32 
 33 
Keywords: Physiological dysregulation, aging, WHAS, InCHIANTI, biomarker, Mahalanobis distance 34 
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Introduction 36 
Many researchers now believe that physiological dysregulation (or related processes such as 37 
allostatic load and homeostenosis) are key players in the aging process, either as causal drivers of aging 38 
or as accompanying processes that nonetheless produce important health consequences (Fried and 39 
others 2005; Karlamangla and others 2002; McEwen and Wingfield 2003; Seplaki and others 2005; 40 
Taffett 2003). These ideas propose that the complex regulatory networks that maintain homeostasis are 41 
not infinitely robust, and that over time the network state might be perturbed in a way that prevents it 42 
from returning fully to a baseline state(Cohen and others 2012). For instance, chronic stress results in 43 
elevated baseline levels of cortisol, with numerous downstream consequences for health; the failure of 44 
cortisol to return to baseline after a stress is an example of dysregulation (Miller and others 2007; 45 
Sapolsky and others 2002). 46 
A number of indices have been proposed to measure allostatic load, mostly for sociological or 47 
epidemiological studies of population health (Crimmins and others 2003; Karlamangla and others 2002; 48 
Seplaki and others 2005; Singer and others 2004; Yashin and others 2007). Most of these indices are 49 
highly predictive of a variety of poor health outcomes (Goymann and Wingfield 2004; Gruenewald and 50 
others 2009; Schnorpfeil and others 2003). However, the indices are generally composed of a number of 51 
biomarkers or criteria already known to indicate poor health; it is thus unsurprising that individuals 52 
doing poorly on multiple such measures have poor health outcomes. Accordingly the measures may be 53 
useful as a summary of health state, but they do not validate the underlying hypothesis that 54 
dysregulation is an important part of aging (Singer and others 2004). 55 
Recently, we proposed a novel way to measure physiological dysregulation based on clinical 56 
biomarkers (Cohen and others 2013). Under the hypothesis that a well-functioning, homeostatic 57 
physiology should be relatively similar across individuals, but that there are many ways in which 58 
physiology might become dysregulated, we proposed statistical distance (specifically Mahalanobis 59 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
4 
 
distance, DM (De Maesschalck and others 2000; Mahalanobis 1936)) as a measure of physiological 60 
dysregulation. DM (applied to biomarkers) is a measure of how strange an individual’s profile is relative 61 
to everyone else in the population, and greater distance should thus measure greater dysregulation. We 62 
applied this measure to a set of 14 biomarkers chosen from the Women’s Health and Aging Study 63 
(WHAS) II data set based on their increase in deviance from the mean with age (but not necessarily 64 
changes in the mean with age), and showed that DM increased with age within individuals and predicted 65 
mortality controlling for age. Additionally, using the combinatorial subsets of the markers, we showed 66 
that results were relatively insensitive to marker choice, but that predictive power increased with 67 
inclusion of more markers in the calculation of DM. It thus appeared that DM is a measure of 68 
physiological dysregulation. 69 
However, a number of further validation steps are necessary before DM can be used widely. We need 70 
to establish sensitivity to marker choice – including a wider array of markers – and to the choice of the 71 
reference population used to define a “normal” biomarker profile. Also, predictive power for relevant 72 
health outcomes needs to be assessed. Here, we tackle the question of reproducibility across 73 
populations/data sets, asking whether similar results for the same 14 markers can be obtained in other 74 
data sets. We use WHAS I (the complement study to WHAS II, including a less health segment of the 75 
population in Baltimore, Maryland, USA) and Invecchiare in Chianti (InCHIANTI), a population-based 76 
cohort study conducted in Tuscany, Italy. 77 
 78 
Methods 79 
Data 80 
The Women’s Health and Aging Study (WHAS) is a population-based prospective study of 81 
community-dwelling women. Originally, WHAS was two separate studies, WHAS I including 1002 women 82 
aged 65+ among the 1/3 most disabled in the population(Fried and others 1995), and WHAS II including 83 
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436 women aged 70-79 among the 2/3 least disabled (Fried and others 2000). The participants were 84 
drawn from eastern Baltimore City and Baltimore County, Maryland. Baseline assessment occurred from 85 
November 1992 to February 1995 in WHAS I and from August 1994 to February 1996 in WHAS II. Eligible 86 
non-participants were less educated, had lower incomes, and had lower self-rated health compared to 87 
WHAS participants. Follow-ups were conducted roughly 1.5, 3, 6, 7.5, and 9 years later. Each 88 
examination consisted of a comprehensive medical history, medication inventory, physical and 89 
neurological examination, neuropsychological battery, and blood draw (Fried and others 2000). Here, 90 
we merge participants from WHAS I and WHAS II into a single data set, WHAS, for comparison with 91 
InCHIANTI. 92 
Invecchiare in Chianti (InCHIANTI) is a prospective population-based study of 1156 adults aged 65-93 
102 and 299 aged 20-64 randomly selected from two towns in Tuscany, Italy using multistage stratified 94 
sampling in 1998 (Ferrucci and others 2000). Follow-up blood and urine samples were taken in 2001-03, 95 
2005-06, and 2007-08. Because InCHIANTI contains both men and younger individuals, we replicate 96 
InCHIANTI analyses on the subset of women aged 70+ in order to have a population comparable to 97 
WHAS II in our previous study. 98 
 99 
Biomarker choice 100 
In our previous study (Cohen and others 2013), 14 biomarkers were chosen from among 63 101 
candidate markers based on a positive correlation of their deviances with age (the deviance is the 102 
absolute value of the marker level minus the population mean). Here, we use the same markers: red 103 
blood cell count, hemoglobin, hematocrit, sodium, chloride, potassium, calcium, cholesterol, albumin, 104 
creatinine, BUN:creatinine ration, basophil count, osteocalcin, and direct bilirubin, although the last two 105 
were not measured in InCHIANTI and are thus excluded from those analyses. We also compared 106 
whether we would have chosen the same set of markers had we applied the same criteria to the data 107 
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sets used here, calculating the correlation of each biomarker with age, and of its deviance with age, in 108 
each population. 109 
 110 
Statistical analyses 111 
All statistical analyses were conducted in R v3.0.1 and code is available upon request. All variables 112 
were log- or square-root-transformed as necessary to approach normality, and then standardized by 113 
subtracting their mean and dividing by their standard deviation. DM was calculated using the following 114 
formula:  115 
                        (1) 116 
where x is a multivariate observation (a vector of simultaneously observed values for the variables in 117 
question, such as all the biomarker values for a given patient at a given time point),  is the equivalent-118 
length vector of population means for each variable, and S is the population variance-covariance matrix 119 
for the variables. The parameters  and S were estimated for each data set) from the first visit of each 120 
individual, both to assure independence of observations and to use a slightly younger, healthier 121 
reference population. Because DM is approximately log-normally distributed, it was log-transformed 122 
before analysis. 123 
Individual changes in DM with age were modeled using linear regression models for each individual to 124 
estimate a slope for each individual; weighted t-tests were then used to assess whether the slope was 125 
significantly different from zero, weighted by the number of observations per individual. The mean slope 126 
per population was thus a measure of rate of change of DM with age. The relationship between DM and 127 
subsequent mortality was modeled using Cox proportional hazards models (coxph function, 128 
survival package) using a time-to-event framework and age as the time variable. 129 
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All analyses were repeated for each combinatorial subset of the variables (16,383 combinations for 130 
the 14 variables in WHAS and 4095 combinations for the 12 variables in InCHIANTI), and meta-131 
regression models were used to assess the impact of the number of variables and which variables were 132 
included on model results. Results were also merged across data sets by biomarker combination to 133 
assess correlations of results across data sets for the same biomarker combinations. All analyses were 134 
repeated for WHAS I, WHAS II, InCHIANTI, WHAS I and II combined, and the subset of InCHIANTI that is 135 
women aged 70+. The latter was chosen to have a population comparable with the original WHAS II 136 
study. 137 
 138 
Results 139 
Correlations of deviances with age were markedly heterogeneous across data sets (Fig. 1). There was 140 
very little correspondence across data sets as to which variables would have been retained for use in DM 141 
(i.e., those with significant positive deviance correlations with age, shaded blue in Fig. 1), with only one 142 
of the original 12 shared across WHAS I, WHAS II, and InCHIANTI. Restricting InCHIANTI to women aged 143 
70+ so that its composition resembled WHAS II did not improve the correspondence. Raw correlations 144 
with age were more often significant than deviance correlations, and showed somewhat greater (but 145 
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not much) consistency across data sets. 146 
 147 
Figure 1: Correlations of raw variables and their deviances with age. Variables are sorted from lowest to highest deviance 148 
correlation coefficient in WHAS II (third column). Colored boxes indicate significant correlations (blue=positive, red=negative) 149 
with darker shading indicating lower p-values. Note that of the 12 original variables retained for WHAS II (those shaded blue at 150 
the bottom), only one would have been retained for WHAS I and four for InCHIANTI. On the other hand, eight additional 151 
variables not retained for WHAS II would have been retained for WHAS I, and 18 for InCHIANTI. 152 
For all data sets, most combinations of biomarkers produced DMs that increased with age (positive 153 
individual slope) and that positively predicted mortality (Figs 2-3). For change with age, 82% of analyses 154 
were significant at α=0.05 in WHAS and 99% in InCHIANTI; for mortality, 73% were significant in WHAS 155 
and 83% in InCHIANTI. Given the consistently positive relationships with mortality (99.9% of models in 156 
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both WHAS and InCHIANTI) and the generally large effect sizes (median hazard ratio per unit DM of 1.27 157 
for WHAS and 1.20 for InCHIANTI), the lower levels of significant results for mortality are likely due to 158 
less statistical power as a result of the relatively limited number of deaths in the data sets (up to 122 in 159 
WHAS and 193 in InCHIANTI, depending on the biomarker combination and missingness).  160 
 161 
Figure 2: Changes in predictive power of DM in WHAS with increasing numbers of variables used in its calculation. Each circle 162 
represents an analysis based on one of the 16383 combinatorial subsets of the 14 variables in WHAS. Color indicates p-value: 163 
black: p ≥ 0.1; blue: 0.05 ≤ p < 0.1; cyan: 0.01 ≤ p < 0.05; yellow-green: 0.001 ≤ p < 0.01; orange: 0.0001 ≤ p < 0.001; red: p < 164 
0.0001. The line represents a linear regression of number of variables on relevant effect size. Effect size trend shows the results 165 
of a Pearson correlation analysis of variable number with relevant effect size. (a)-(c): average individual slope of DM with age 166 
(units of increase in DM per year). (d)-(f): hazard ratio of mortality per unit DM, controlling for age. (a), (d): The full WHAS data 167 
set. (b), (e): WHAS I. (c), (f): WHAS II.  168 
In all cases there was a significant tendency to have stronger predictions with more variables 169 
included in the calculation of DM (Figs 2-3). In general this effect was quite large, with age slopes 170 
generally about twice as large when DM was calculated with the maximum 14 or 12 variables, compared 171 
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to just one variable. Hazard ratios were often 50% larger with maximum number of variables, except for 172 
in WHAS II, where the effect was negligible (Fig. 2f).  173 
 174 
Figure 3: Changes in predictive power of DM in InCHIANTI with increasing numbers of variables used in its calculation. Each 175 
circle represents an analysis based on one of the 4095 combinatorial subsets of the 12 variables in InCHIANTI. Color indicates p-176 
value: black: p ≥ 0.1; blue: 0.05 ≤ p < 0.1; cyan: 0.01 ≤ p < 0.05; yellow-green: 0.001 ≤ p < 0.01; orange: 0.0001 ≤ p < 0.001; red: 177 
p < 0.0001. The line represents a linear regression of number of variables on relevant effect size. Effect size trend shows the 178 
results of a Pearson correlation analysis of variable number with relevant effect size. (a) and (b): average individual slope of DM 179 
with age (units of increase in DM per year). (c) and (c): hazard ratio of mortality per unit DM, controlling for age. (a) and (c): The 180 
full InCHIANTI data set. (b) and (d): The subset of women aged 70+ (for comparison with the original WHAS II data set). 181 
We also tested whether results were correlated between WHAS and InCHIANTI for the same variable 182 
combination. For slope with age, the correlation was quite strong (r=0.74, p<0.0001), but this was 183 
mostly due to the inclusion or exclusion of one variable, basophil count. Stratifying by basophil count, 184 
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the correlation was much weaker (r=0.22 with basophils and r=0.26 without, p<0.0001 for both). This 185 
was similar to the correlation for hazard ratios (r=0.28, p<0.0001). These correlations are surprisingly 186 
weak: the performance of models in one data set explains only 5-8% of the variance the performance in 187 
the other (calculated as the squares of the pairwise correlation coefficients). 188 
Results were also quite heterogeneous for the effects of including or excluding each biomarker in the 189 
calculation of DM (Table 1). Almost all the effects (89%) were significant at α=0.05, but in all but six of 190 
the 28 cases (14 variables  2 outcomes) these significant effects went in opposing directions depending 191 
on the data set or subset. The six cases were as follows: including creatinine, BUN:creatinine ratio, and 192 
osteocalcin significantly increased the slope with age, and including bilirubin, sodium, and cholesterol 193 
significantly increased hazard ratios. The effect for osteocalcin was quite large, explaining the nearly 194 
separate point clouds in Fig 2c. Despite one result to the contrary for WHAS II, including basophil count 195 
also appears to have a generally strong, positive effect on slope, explaining the separate point clouds in 196 
Fig. 3a-b for InCHIANTI. Note, however, that the variables that improve model performance for change 197 
in DM with age are not the same as those that improve mortality prediction.198 
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Table 1: Results of metagregression analyses to assess the impact of including or excluding each variable in the calculation of DM 199 
    WHAS (all)   WHAS I   WHAS II   InCHIANTI   InCHIANTI F70+ 
  
β p 
 
β p 
 
β p 
 
β p 
 
β p 
Individual slope with age 
              
 
Albumin -0.018 <0.0001 
 
-0.009 <0.0001 
 
-0.005 0.00 
 
0.010 <0.0001 
 
-0.002 0.23 
 
Hemoglobin -0.013 <0.0001 
 
0.006 0.0001 
 
-0.009 <0.0001 
 
0.004 0.008 
 
0.001 0.35 
 
Hematocrit -0.011 <0.0001 
 
0.021 <0.0001 
 
-0.013 <0.0001 
 
0.012 <0.0001 
 
0.012 <0.0001 
 
Chloride -0.008 <0.0001 
 
-0.028 <0.0001 
 
0.007 <0.0001 
 
0.008 <0.0001 
 
0.014 <0.0001 
 
RBCs -0.003 0.003 
 
0.004 0.003 
 
0.003 0.06 
 
-0.005 0.0001 
 
0.001 0.50 
 
Cholesterol 0.000 0.85 
 
0.015 <0.0001 
 
0.001 0.37 
 
-0.006 <0.0001 
 
0.009 <0.0001 
 
Calcium 0.001 0.44 
 
0.010 <0.0001 
 
-0.016 <0.0001 
 
0.003 0.01 
 
-0.007 <0.0001 
 
Bilirubin (direct) 0.003 0.003 
 
-0.003 0.07 
 
0.016 <0.0001 
      
 
Sodium 0.006 <0.0001 
 
-0.006 <0.0001 
 
0.020 <0.0001 
 
0.006 <0.0001 
 
0.001 0.52 
 
Potassium 0.012 <0.0001 
 
0.021 <0.0001 
 
-0.002 0.18 
 
-0.004 0.001 
 
-0.003 0.06 
 
BUN:Creat ratio 0.019 <0.0001 
 
0.004 0.003 
 
0.029 <0.0001 
 
0.012 <0.0001 
 
0.014 <0.0001 
 
Creatinine 0.028 <0.0001 
 
0.028 <0.0001 
 
0.009 <0.0001 
 
0.018 <0.0001 
 
0.023 <0.0001 
 
Basophils 0.038 <0.0001 
 
0.13 <0.0001 
 
-0.011 <0.0001 
 
0.080 <0.0001 
 
0.089 <0.0001 
 
Osteocalcin 0.12 <0.0001 
 
0.11 <0.0001 
 
0.19 <0.0001 
      
Mortality (HR) 
              
 
Calcium -0.025 <0.0001 
 
-0.032 <0.0001 
 
-0.019 <0.0001 
 
0.004 0.002 
 
-0.002 0.29 
 
Creatinine -0.008 <0.0001 
 
0.038 <0.0001 
 
-0.143 <0.0001 
 
0.056 <0.0001 
 
0.055 <0.0001 
 
RBCs -0.004 <0.0001 
 
-0.009 <0.0001 
 
0.009 <0.0001 
 
-0.012 <0.0001 
 
-0.015 <0.0001 
 
Albumin 0.002 0.04 
 
0.021 <0.0001 
 
0.006 <0.0001 
 
0.022 <0.0001 
 
0.028 <0.0001 
 
Osteocalcin 0.003 0.0002 
 
-0.039 <0.0001 
 
0.033 <0.0001 
      
 
Basophils 0.006 <0.0001 
 
-0.011 <0.0001 
 
0.039 <0.0001 
 
-0.020 <0.0001 
 
-0.058 <0.0001 
 
Potassium 0.008 <0.0001 
 
-0.006 <0.0001 
 
0.023 <0.0001 
 
-0.003 0.02 
 
0.004 0.02 
 
Hematocrit 0.009 <0.0001 
 
0.012 <0.0001 
 
-0.004 0.005 
 
-0.003 0.05 
 
0.002 0.35 
 
Hemoglobin 0.009 <0.0001 
 
0.013 <0.0001 
 
0.004 0.005 
 
-0.008 <0.0001 
 
-0.004 0.03 
 
Cholesterol 0.012 <0.0001 
 
0.000 0.93 
 
0.016 <0.0001 
 
0.027 <0.0001 
 
0.027 <0.0001 
 
Sodium 0.021 <0.0001 
 
0.022 <0.0001 
 
0.009 <0.0001 
 
0.035 <0.0001 
 
0.025 <0.0001 
 
Chloride 0.024 <0.0001 
 
0.034 <0.0001 
 
0.006 0.0001 
 
-0.002 0.20 
 
-0.022 <0.0001 
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BUN:Creat ratio 0.042 <0.0001 
 
0.057 <0.0001 
 
-0.011 <0.0001 
 
0.014 <0.0001 
 
0.023 <0.0001 
  Bilirubin (direct) 0.062 <0.0001   0.068 <0.0001   0.049 <0.0001             
Betas indicate change in effect size with the inclusion of the biomarker. Biomarkers are ordered by their beta-coefficients for the full WHAS data set, 
separately for individual slope with age and mortality. Negative coefficients are marked in red; coefficients not significant at alpha=0.05 are in italics. 
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Discussion 200 
The results presented here confirm and expand on our previous study showing that statistical 201 
distance is a promising measure for physiological dysregulation during aging (Cohen and others 2013). 202 
By using additional data sets (WHAS I and InCHIANTI), we are able to provide independent confirmation 203 
of those results, results which are nearly identical in terms of the big picture (Figs 2-3), but which are 204 
also surprisingly different in the details. In all data sets, DM significantly increases with age within 205 
individuals, and significantly predicts mortality. Likewise, in all cases predictions improve as more 206 
variables are included in the calculation of DM. These three findings confirm key predictions about how 207 
DM should behave if it is truly a measure of physiological dysregulation (Cohen and others 2013). 208 
One of the key challenges in developing a measure of physiological dysregulation is to avoid 209 
circularity (Singer and others 2004). It is unsurprising that by combining multiple measures of poor 210 
health one arrives at a measure that predicts poor health or age. Statistical distance, as measured by DM, 211 
circumvents this problem by asking not if each patient is badly off on each marker, but by asking 212 
whether the overall profile of markers is far from average, regardless of how we define a healthy state 213 
for each. Additionally, we specifically did not restrict marker choice to those known to change with age 214 
or with health status; electrolyte levels, for example, are generally quite stable outside of specific 215 
pathologies. However, in our original study, we did impose the criterion that the deviance of markers 216 
from their mean be positively correlated with age (i.e., more aberrant values at older ages) in order to 217 
try to choose markers that would provide a stronger signal (Cohen and others 2013). Here, we showed 218 
that even this criterion is largely irrelevant – the correlations of individual markers with age are often 219 
quite heterogeneous across data sets and even subsets, and the correlations of the deviances with age 220 
are even more so. We would have chosen a completely different suite of markers had our original data 221 
set been a different one; nonetheless, using the markers chosen based on WHAS II, we get nearly 222 
identical results in all the data sets. 223 
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Likewise, we expected that a given combination of markers would provide a similar signal in different 224 
data sets, but the correlations were surprisingly weak. In each data set, the inclusion or exclusion of 225 
each marker was almost always significantly associated with model performance, but the directions of 226 
these associations varied across data sets, and few markers showed consistent effects across data sets. 227 
No markers showed consistent effects both (a) predicting both age and mortality, and (b) across data 228 
sets. In other words, if we find that including a given marker in the calculation of DM improves the 229 
performance of DM in one data set, we cannot necessarily make any inferences from this toward other 230 
data sets, at least among the markers used here. 231 
How can we explain these relatively inconsistent results model-by-model, despite consistent results 232 
at a higher level? We believe that the discrepancies across data sets are, counterintuitively, a 233 
confirmation of the generality of DM as a measure of dysregulation. If the performance of DM depended 234 
too heavily on the choice of marker, it would suggest that DM is not a measure of generalized 235 
dysregulatory state, but rather of what is happening with several key markers. Heterogeneity of results 236 
suggests that the effects of each marker of DM performance depend on small differences across data 237 
sets in terms of population composition, diet, lifestyle, underlying physiology, and so forth; nonetheless, 238 
by combining a sufficient number of markers (and without much regard for which) we are able to 239 
circumvent these details and arrive at a fairly robust, generalized signal of dysregulatory state. Given 240 
what is known about the complexity of physiological regulation, this is in fact exactly the prediction we 241 
would make if DM truly represents physiological dysregulation.  242 
At a practical level, this study supports the utility of DM as a measure of dysregulation or generalized 243 
health state, whether it be in studies of aging epidemiology, sociological or economic studies of 244 
population health, or in clinic. Clinical frailty measures such as Fried’s frailty criteria (Fried and others 245 
2001) and the Frailty Index (Rockwood and others 2005) provide useful insight into functional decline 246 
during aging (Clegg and others 2013); DM promises to be a complementary measure of the underlying 247 
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physiology. While frailty measures are most powerful late in life, DM appears to pick up a signal much 248 
younger, suggesting clinical applications in prevention and non-geriatric populations, as well as 249 
coordinated use with frailty measures. 250 
However, several further validation steps are necessary before implementing DM widely. First, 251 
robustness/sensitivity to marker choice and number needs to be established across a wider array of 252 
markers, and recommended optimal marker combinations should be established. Second, we need to 253 
understand the sensitivity to reference population (the population used to establish the definition of a 254 
“normal” or “average” profile). Given that most of the individuals used here were already elderly and 255 
thus in poorer health, there may be a potential to achieve better performance using younger and/or 256 
healthier populations to compute  and S in equation (1). Third, predictive value of DM for specific 257 
health outcomes such as frailty and cardiovascular disease needs to be assessed. Fourth, we will need to 258 
analyze whether there is a single global dysregulatory process, or if dysregulation can be usefully 259 
subdivided by physiological or biological system, and, in the latter case, if these dysregulations are 260 
correlated.  261 
While such validation is essential before systematic implementation, current results are strong 262 
enough to suggest that DM could be useful immediately in smaller-scale studies. For example, we were 263 
recently able to successfully predict two measures of health state in a population of wild birds based on 264 
DM calculated from 11 biomarkers available in an existing data set (Milot and others 2013). Additionally, 265 
at a theoretical level, this study confirms the interpretation of DM as a measure of physiological 266 
dysregulation, as well as a role for physiological dysregulation in the aging process. It suggests strongly 267 
that too much emphasis on any single molecule may be misleading (as seen from our differing results for 268 
each molecule across data sets), and that measures of system-level properties of regulatory state will be 269 
necessary to better understand the aging process. 270 
 271 
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